{
    "Clinical Trial ID": "NCT00375505",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Placebo",
        "  Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).",
        "INTERVENTION 2: ",
        "  Zometa",
        "  Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Female patients with histologically confirmed incident invasive breast cancer (T1-4) with positive hormone receptor status (ER and/or PgR positive) and no evidence of regional lymph node metastasis (N0) or distant metastasis (M0)",
        "  Patient has undergone complete primary tumor resection and axillary lymph node dissection less than 90 days before start of study drug treatment.",
        "  Patient is premenopausal at diagnosis of breast cancer (spontaneous and regular menses with premenopausal estradiol levels (>10 ng/dL)",
        "  Patient receives adjuvant standard chemoendocrine or endocrine therapy",
        "  Bone density at study entry > -2.5 T-Score",
        "Exclusion Criteria:",
        "  History of treatment or disease affecting bone metabolism (e.g., Paget's disease, primary hyperparathyroidism), prior treatment with bisphosphonates or treatments for osteoporosis in addition to calcium and vitamin D",
        "  Abnormal renal function",
        "  Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures, recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)",
        "  Pregnancy or lactation",
        "  Women of childbearing potential not applying a medically recognized form of contraception (i.e., oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide)",
        "  Other protocol-defined inclusion/exclusion criteria may apply"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24",
        "  Bone mineral density (BMD) by DXA at lumbar spine (L2-L4); DXA assessments of the BMD at dual hips. (BMD). Two X-ray beams with different energy levels are aimed at the patient's bones. When soft tissue absorption is subtracted out, the BMD can be determined from the absorption of each beam by bone.",
        "  Time frame: baseline, month 24",
        "Results 1: ",
        "  Arm/Group Title: Placebo",
        "  Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).",
        "  Overall Number of Participants Analyzed: 36",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Z-score  -0.075         (0.041)",
        "Results 2: ",
        "  Arm/Group Title: Zometa",
        "  Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).",
        "  Overall Number of Participants Analyzed: 34",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Z-score  0.037         (0.042)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 3/36 (8.33%)",
        "  VERTIGO 0/36 (0.00%)",
        "  DENTAL CARIES 1/36 (2.78%)",
        "  GASTROINTESTINAL OEDEMA 1/36 (2.78%)",
        "  HAEMATOCHEZIA 0/36 (0.00%)",
        "  PANCREATITIS 1/36 (2.78%)",
        "  PYREXIA 1/36 (2.78%)",
        "  DRUG HYPERSENSITIVITY 0/36 (0.00%)",
        "  FEBRILE INFECTION 0/36 (0.00%)",
        "  SUBCUTANEOUS ABSCESS 1/36 (2.78%)",
        "  OSTEONECROSIS 0/36 (0.00%)",
        "  BREAST CANCER 1/36 (2.78%)",
        "  OSTEOMA 1/36 (2.78%)",
        "Adverse Events 2:",
        "  Total: 6/34 (17.65%)",
        "  VERTIGO 1/34 (2.94%)",
        "  DENTAL CARIES 0/34 (0.00%)",
        "  GASTROINTESTINAL OEDEMA 0/34 (0.00%)",
        "  HAEMATOCHEZIA 1/34 (2.94%)",
        "  PANCREATITIS 0/34 (0.00%)",
        "  PYREXIA 0/34 (0.00%)",
        "  DRUG HYPERSENSITIVITY 1/34 (2.94%)",
        "  FEBRILE INFECTION 1/34 (2.94%)",
        "  SUBCUTANEOUS ABSCESS 0/34 (0.00%)",
        "  OSTEONECROSIS 1/34 (2.94%)",
        "  BREAST CANCER 1/34 (2.94%)",
        "  OSTEOMA 0/34 (0.00%)"
    ]
}